Zenas BioPharma, ETF Leadership
| ZBIO Etf | USD 8.33 0.19 2.23% |
Zenas BioPharma, employs about 130 people. The company is managed by 7 executives with a total tenure of roughly 304 years, averaging almost 43.0 years of service per executive, having 18.57 employees per reported executive. Analysis of Zenas BioPharma,'s management performance can provide insight into the ETF performance.
| Jennifer Fox CFO Chief CFO |
| Orlando Oliveira Executive Chief Officer |
Zenas |
Zenas BioPharma, Management Team Effectiveness
Zenas BioPharma,'s management efficiency ratios could be used to measure how well Zenas BioPharma, manages its routine affairs as well as how well it operates its assets and liabilities.Zenas BioPharma, Workforce Comparison
Zenas BioPharma, Common is rated fifth in number of employees as compared to similar ETFs. The total workforce of Health Care category is currently estimated at about 7,999. Zenas BioPharma, claims roughly 130 in number of employees contributing just under 2% to all ETFs under Health Care category.
Zenas BioPharma, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zenas BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zenas BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zenas BioPharma, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Moulder Leon O Jr over a month ago Acquisition by Moulder Leon O Jr of 25000 shares of Zenas BioPharma, at 6.67 subject to Rule 16b-3 | ||
Xiao Ting over a month ago Acquisition by Xiao Ting of 10000 shares of Zenas BioPharma, at 7.76 subject to Rule 16b-3 | ||
Orlando Oliveira over three months ago Acquisition by Orlando Oliveira of 7775 shares of Zenas BioPharma, at 8.77 subject to Rule 16b-3 | ||
Moulder Leon O Jr over three months ago Acquisition by Moulder Leon O Jr of 45000 shares of Zenas BioPharma, at 9.98 subject to Rule 16b-3 | ||
Moulder Leon O Jr over three months ago Acquisition by Moulder Leon O Jr of 25000 shares of Zenas BioPharma, at 10.76 subject to Rule 16b-3 | ||
Moulder Leon O Jr over three months ago Acquisition by Moulder Leon O Jr of 2500 shares of Zenas BioPharma, at 14.57 subject to Rule 16b-3 | ||
Moulder Leon O Jr over three months ago Acquisition by Moulder Leon O Jr of 7500 shares of Zenas BioPharma, at 15.0 subject to Rule 16b-3 |
Zenas BioPharma, Notable Stakeholders
A Zenas BioPharma, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zenas BioPharma, often face trade-offs trying to please all of them. Zenas BioPharma,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zenas BioPharma,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MBA Moulder | CEO Board | Profile | |
| Joseph Farmer | COO President | Profile | |
| Jennifer Fox | Chief CFO | Profile | |
| Orlando Oliveira | Chief Officer | Profile | |
| Caroline Chevalier | Chief Officer | Profile | |
| Lisa MD | Head Officer | Profile | |
| Jeffrey Held | Chief Officer | Profile |
About Zenas BioPharma, Management Performance
The success or failure of an entity such as Zenas BioPharma, Common often depends on how effective the management is. Zenas BioPharma, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zenas management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zenas management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.
The data published in Zenas BioPharma,'s official financial statements typically reflect Zenas BioPharma,'s business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Zenas BioPharma,'s quantitative information. For example, before you start analyzing numbers published by Zenas accountants, it's essential to understand Zenas BioPharma,'s liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Zenas BioPharma, Workforce Analysis
Traditionally, organizations such as Zenas BioPharma, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zenas BioPharma, within its industry.Zenas BioPharma, Manpower Efficiency
Return on Zenas BioPharma, Manpower
| Revenue Per Employee | 38.5K | |
| Revenue Per Executive | 714.3K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 22.4M | |
| Working Capital Per Employee | 2.3M | |
| Working Capital Per Executive | 42.7M |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.